The Basics of Radiation Oncology

Opinion
Video

Radiation oncologists Nina Sanford, MD, and Jeffrey M. Ryckman, MD, provide an overview of treatment modalities, highlighting SRS, SBRT, proton therapy, and how options have improved.

Recent Videos
3 experts in this video
Related Content
Survival benefits were observed across most post-hoc subgroups treated with anlotinib plus penpulimab, particularly among those with high-risk disease features.

Anlotinib/Penpulimab Enhances Survival vs Sorafenib in Unresectable HCC

Roman Fabbricatore
May 30th 2025
Article

Survival benefits were observed across most post-hoc subgroups treated with anlotinib plus penpulimab, particularly among those with high-risk disease features.

Govindarajan Narayanan, MD, speaks to the potential time-saving advantages of using the Epione robot for microwave ablation, cryoablation, and other surgical strategies in patients with liver cancer and other tumors.

Adapting to a Robotic Workstation for Image-Guided Liver Cancer Surgery

Govindarajan Narayanan, MD
December 4th 2023
Podcast

Govindarajan Narayanan, MD, speaks to the potential time-saving advantages of using the Epione robot for microwave ablation, cryoablation, and other surgical strategies in patients with liver cancer and other tumors.

SBRT Shows Positive 3-Year OS Rate in Newly Diagnosed Early-Stage HCC

SBRT Shows Positive 3-Year OS Rate in Newly Diagnosed Early-Stage HCC

Tim Cortese
April 26th 2025
Article

SBRT demonstrated positive 3-year outcomes as a treatment in patients with early-stage HCC based on results from the phase 2 STRSPH trial.

MEV01 trial results show that the test achieved an 86% early-stage sensitivity and 88% specificity in surveillance of HCC among patients with cirrhosis.

FDA Grants EvoLiver Biopsy Test Breakthrough Device Designation for HCC

Roman Fabbricatore
April 23rd 2025
Article

MEV01 trial results show that the test achieved an 86% early-stage sensitivity and 88% specificity in surveillance of HCC among patients with cirrhosis.

FDA OKs Nivolumab/Ipilimumab in Unresectable/Metastatic HCC

FDA OKs Nivolumab/Ipilimumab in Unresectable/Metastatic HCC

Ariana Pelosci;Tim Cortese
April 11th 2025
Article

Results from the phase 3 CheckMate 9DW trial of nivolumab/ipilimumab vs lenvatinib or sorafenib led to the approval for patients with unresectable or metastatic HCC.

Most recently, the FDA accepted a second NDA for camrelizumab/rivoceranib as a treatment for patients with unresectable HCC in October 2024.

FDA Issues Second Camrelizumab/Rivoceranib CRL in Hepatocellular Carcinoma

Roman Fabbricatore;Russ Conroy
March 21st 2025
Article

The complete response letter for camrelizumab/rivoceranib for patients with advanced HCC did not specify what deficiencies regulators found.